These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38127829)
21. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related]
23. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277 [TBL] [Abstract][Full Text] [Related]
24. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. Moore SW; Appfelstaedt J; Zaahl MG J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543 [TBL] [Abstract][Full Text] [Related]
25. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198 [TBL] [Abstract][Full Text] [Related]
27. Genetics of medullary thyroid cancer: An overview. Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408 [TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity. Zhu W; Hai T; Ye L; Cote GJ J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677 [TBL] [Abstract][Full Text] [Related]
29. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208 [TBL] [Abstract][Full Text] [Related]
30. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. Chang CF; Yang WS; Su YN; Wu IL; Chang TC J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294 [TBL] [Abstract][Full Text] [Related]
31. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843 [TBL] [Abstract][Full Text] [Related]
32. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. Cerrato A; De Falco V; Santoro M J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830 [TBL] [Abstract][Full Text] [Related]
33. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668 [TBL] [Abstract][Full Text] [Related]
34. Modifying impact of Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230 [TBL] [Abstract][Full Text] [Related]
35. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427 [TBL] [Abstract][Full Text] [Related]
36. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients. Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290 [TBL] [Abstract][Full Text] [Related]
37. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. Machens A; Dralle H World J Surg; 2007 May; 31(5):957-68. PubMed ID: 17453286 [TBL] [Abstract][Full Text] [Related]
38. Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation. Machens A; Lorenz K; Weber F; Dralle H Eur J Surg Oncol; 2021 Apr; 47(4):920-923. PubMed ID: 32962888 [TBL] [Abstract][Full Text] [Related]
39. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926 [TBL] [Abstract][Full Text] [Related]